View Future GrowthLabGenomics 과거 순이익 실적과거 기준 점검 0/6LabGenomics 의 수입은 연평균 -69.8%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 15.2%의 비율로 증가했습니다. 매출은 연평균 20.7%의 비율로 감소해 왔습니다.핵심 정보-69.85%순이익 성장률-69.74%주당순이익(EPS) 성장률Biotechs 산업 성장률11.70%매출 성장률-20.71%자기자본이익률-42.71%순이익률-75.67%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩21.00 loss per share (vs ₩232 profit in 3Q 2022)Third quarter 2023 results: ₩21.00 loss per share (down from ₩232 profit in 3Q 2022). Revenue: ₩21.2b (down 14% from 3Q 2022). Net loss: ₩1.55b (down 120% from profit in 3Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩1,429 (vs ₩2,481 in FY 2021)Full year 2022 results: EPS: ₩1,429 (down from ₩2,481 in FY 2021). Revenue: ₩144.8b (down 28% from FY 2021). Net income: ₩48.4b (down 42% from FY 2021). Profit margin: 33% (down from 41% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updatesNew Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 70% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (₩85.9b market cap, or US$56.3m).공시 • May 22LabGenomics Co., Ltd. announced that it has received KRW 20 billion in fundingOn May 20, 2026, LabGenomics Co., Ltd. has closed the transaction.공시 • May 13LabGenomics Co., Ltd. announced that it expects to receive KRW 20 billion in fundingLabGenomics Co., Ltd. announces a private placement with Stick Litmus Co., Ltd. to issue Series 5 Unregistered Unsecured Private Convertible Bonds for gross proceeds of KRW 20,000,000,000 on May 12, 2026. Expected closing date of the transaction is May 20, 2026. Interest rate of the Notes is 0% and Maturity interest rate is 5%. Maturity date of the Notes is May 20, 2029. Notes are convertible into 13,642,564 shares at a conversion price of KRW 1,466. Conversion billing period starts from May 20, 2027 and ends on April 20, 2029.공시 • Feb 28LabGenomics Co., Ltd., Annual General Meeting, Mar 31, 2026LabGenomics Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea분석 기사 • Jan 28Little Excitement Around LabGenomics Co., Ltd.'s (KOSDAQ:084650) RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.5x LabGenomics Co., Ltd. ( KOSDAQ:084650 ) is definitely...New Risk • Dec 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩141.1b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 57% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩141.1b market cap, or US$96.4m).분석 기사 • Oct 28LabGenomics Co., Ltd.'s (KOSDAQ:084650) Price Is Right But Growth Is LackingWith a price-to-sales (or "P/S") ratio of 2.1x LabGenomics Co., Ltd. ( KOSDAQ:084650 ) may be sending very bullish...New Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 30% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).분석 기사 • May 19Insufficient Growth At LabGenomics Co., Ltd. (KOSDAQ:084650) Hampers Share PriceLabGenomics Co., Ltd.'s ( KOSDAQ:084650 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a strong buy...분석 기사 • Apr 08Is LabGenomics (KOSDAQ:084650) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...공시 • Feb 21LabGenomics Co., Ltd., Annual General Meeting, Mar 26, 2025LabGenomics Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South KoreaNew Risk • Jan 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 25% per year over the past 5 years.분석 기사 • Jan 06There's No Escaping LabGenomics Co., Ltd.'s (KOSDAQ:084650) Muted Revenues Despite A 46% Share Price RiseLabGenomics Co., Ltd. ( KOSDAQ:084650 ) shareholders would be excited to see that the share price has had a great...분석 기사 • Nov 17Not Many Are Piling Into LabGenomics Co., Ltd. (KOSDAQ:084650) Stock Yet As It Plummets 26%Unfortunately for some shareholders, the LabGenomics Co., Ltd. ( KOSDAQ:084650 ) share price has dived 26% in the last...분석 기사 • Nov 08Is LabGenomics (KOSDAQ:084650) Weighed On By Its Debt Load?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Sep 21Slammed 29% LabGenomics Co., Ltd. (KOSDAQ:084650) Screens Well Here But There Might Be A CatchLabGenomics Co., Ltd. ( KOSDAQ:084650 ) shares have retraced a considerable 29% in the last month, reversing a fair...New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change).분석 기사 • Aug 06Market Might Still Lack Some Conviction On LabGenomics Co., Ltd. (KOSDAQ:084650) Even After 35% Share Price BoostLabGenomics Co., Ltd. ( KOSDAQ:084650 ) shares have had a really impressive month, gaining 35% after a shaky period...New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).분석 기사 • Jul 27Is LabGenomics (KOSDAQ:084650) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...분석 기사 • Apr 09Market Still Lacking Some Conviction On LabGenomics Co., Ltd. (KOSDAQ:084650)LabGenomics Co., Ltd.'s ( KOSDAQ:084650 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...New Risk • Mar 28New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Nov 21Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩4,050, the stock trades at a trailing P/E ratio of 72.7x. Average forward P/E is 40x in the Biotechs industry in South Korea. Total returns to shareholders of 9.9% over the past three years.Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩21.00 loss per share (vs ₩232 profit in 3Q 2022)Third quarter 2023 results: ₩21.00 loss per share (down from ₩232 profit in 3Q 2022). Revenue: ₩21.2b (down 14% from 3Q 2022). Net loss: ₩1.55b (down 120% from profit in 3Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩3,670, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 28% over the past three years.Buying Opportunity • Sep 25Now 23% undervaluedOver the last 90 days, the stock is up 35%. The fair value is estimated to be ₩6,026, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last 3 years. Earnings per share has grown by 4.3%.Valuation Update With 7 Day Price Move • Aug 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩5,420, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 9.3% over the past three years.New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Share price has been volatile over the past 3 months (8.5% average weekly change). Profit margins are more than 30% lower than last year (18% net profit margin). Shareholders have been diluted in the past year (9.2% increase in shares outstanding).Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩9,830, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 26% over the past three years.Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩8,200, the stock trades at a trailing P/E ratio of 21x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total loss to shareholders of 9.6% over the past three years.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩6,470, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 5.5% over the past three years.Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩1,429 (vs ₩2,481 in FY 2021)Full year 2022 results: EPS: ₩1,429 (down from ₩2,481 in FY 2021). Revenue: ₩144.8b (down 28% from FY 2021). Net income: ₩48.4b (down 42% from FY 2021). Profit margin: 33% (down from 41% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Mar 16Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩5,480, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 3.3% over the past three years.공시 • Jan 19LabGenomics Co., Ltd. announced that it has received KRW 22.71198072 billion in fundingOn January 18, 2023, LabGenomics Co., Ltd. closed the transaction. The company amended the terms of the transaction. The company issued 3,128,372 shares at an issue price of KRW 7,260 per share for gross proceeds of KRW 22,711,980,720. The transaction included participation from Ruha Galacticos Co., Ltd., for 3,128,372 shares.Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 21 April 2023. Payout ratio is a comfortable 4.5% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Oct 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩6,400, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 319% over the past three years.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩6,910, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 343% over the past three years.Valuation Update With 7 Day Price Move • Aug 25Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to ₩6,780, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 369% over the past three years.Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩6,980, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 268% over the past three years.Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to ₩7,090, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 177% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Mar 16Investor sentiment improved over the past weekAfter last week's 41% share price gain to ₩31,700, the stock trades at a trailing P/E ratio of 5.5x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 334% over the past three years.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₩29,400, the stock trades at a trailing P/E ratio of 5.1x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total returns to shareholders of 329% over the past three years.Valuation Update With 7 Day Price Move • Dec 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩25,900, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 39x in the Biotechs industry in South Korea. Total returns to shareholders of 332% over the past three years.Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improved over the past weekAfter last week's 33% share price gain to ₩31,400, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 394% over the past three years.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩24,750, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 38x in the Biotechs industry in South Korea. Total returns to shareholders of 205% over the past three years.Valuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩29,250, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 221% over the past three years.Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩34,300, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 43x in the Biotechs industry in South Korea. Total returns to shareholders of 321% over the past three years.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩32,550, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 48x in the Biotechs industry in South Korea. Total returns to shareholders of 272% over the past three years.Valuation Update With 7 Day Price Move • May 28Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩23,350, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 116% over the past three years.Valuation Update With 7 Day Price Move • Apr 26Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₩27,600, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 54x in the Biotechs industry in South Korea. Total returns to shareholders of 150% over the past three years.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩22,350, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 50x in the Biotechs industry in South Korea. Total returns to shareholders of 55% over the past three years.분석 기사 • Mar 31If You Like EPS Growth Then Check Out LabGenomics (KOSDAQ:084650) Before It's Too LateIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...Is New 90 Day High Low • Feb 22New 90-day low: ₩15,300The company is down 33% from its price of ₩22,750 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Jan 15New 90-day low: ₩15,850The company is down 54% from its price of ₩34,550 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 22% over the same period.Is New 90 Day High Low • Dec 28New 90-day low: ₩17,500The company is down 51% from its price of ₩35,500 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period.Is New 90 Day High Low • Dec 08New 90-day low: ₩20,600The company is down 48% from its price of ₩39,850 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.Is New 90 Day High Low • Nov 10New 90-day low: ₩27,300The company is down 33% from its price of ₩40,800 on 12 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 22New 90-day low: ₩31,650The company is down 22% from its price of ₩40,450 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period.매출 및 비용 세부 내역LabGenomics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A084650 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2684,190-63,70872,3121,42531 Dec 2588,161-64,37574,4331,87130 Sep 2589,364-35,81254,5842,15830 Jun 2587,971-35,04055,9102,32831 Mar 2587,900-20,13440,3252,42931 Dec 2485,898-23,58338,9222,68130 Sep 2483,745-22,16840,0593,06830 Jun 2483,275-21,00738,0892,84131 Mar 2476,293-17,90034,5592,55931 Dec 2371,076-4,71930,1232,62430 Sep 2369,8484,13525,5532,39030 Jun 2373,18813,55823,3892,29031 Mar 2379,80414,48324,7151,80731 Dec 22144,77348,39726,1701,86530 Sep 22187,00974,15123,5001,39830 Jun 22215,95290,80023,0801,28931 Mar 22248,011108,70221,2841,49031 Dec 21202,40783,85518,48455730 Sep 21173,03964,68218,26425630 Jun 21146,33649,14816,751031 Mar 21141,63253,80216,334031 Dec 20119,47842,76615,213030 Sep 2097,27938,38213,993030 Jun 2078,95629,47913,079031 Mar 2038,2373,17510,720031 Dec 1933,17596210,6990양질의 수익: A084650 은(는) 현재 수익성이 없습니다.이익 마진 증가: A084650는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A084650은 수익성이 없으며 지난 5년 동안 손실이 연평균 69.8% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A084650의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A084650은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(22.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A084650는 현재 수익성이 없으므로 자본 수익률이 음수(-42.71%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/07 20:39종가2026/07/07 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스LabGenomics Co., Ltd.는 4명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hyung Soo KimHanwha Investment & Securities Co., Ltd.Wan KuiM SecuritiesKyung-Churl NohSK Securities Co., Ltd.1명의 분석가 더 보기
Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩21.00 loss per share (vs ₩232 profit in 3Q 2022)Third quarter 2023 results: ₩21.00 loss per share (down from ₩232 profit in 3Q 2022). Revenue: ₩21.2b (down 14% from 3Q 2022). Net loss: ₩1.55b (down 120% from profit in 3Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩1,429 (vs ₩2,481 in FY 2021)Full year 2022 results: EPS: ₩1,429 (down from ₩2,481 in FY 2021). Revenue: ₩144.8b (down 28% from FY 2021). Net income: ₩48.4b (down 42% from FY 2021). Profit margin: 33% (down from 41% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
New Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 70% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (₩85.9b market cap, or US$56.3m).
공시 • May 22LabGenomics Co., Ltd. announced that it has received KRW 20 billion in fundingOn May 20, 2026, LabGenomics Co., Ltd. has closed the transaction.
공시 • May 13LabGenomics Co., Ltd. announced that it expects to receive KRW 20 billion in fundingLabGenomics Co., Ltd. announces a private placement with Stick Litmus Co., Ltd. to issue Series 5 Unregistered Unsecured Private Convertible Bonds for gross proceeds of KRW 20,000,000,000 on May 12, 2026. Expected closing date of the transaction is May 20, 2026. Interest rate of the Notes is 0% and Maturity interest rate is 5%. Maturity date of the Notes is May 20, 2029. Notes are convertible into 13,642,564 shares at a conversion price of KRW 1,466. Conversion billing period starts from May 20, 2027 and ends on April 20, 2029.
공시 • Feb 28LabGenomics Co., Ltd., Annual General Meeting, Mar 31, 2026LabGenomics Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
분석 기사 • Jan 28Little Excitement Around LabGenomics Co., Ltd.'s (KOSDAQ:084650) RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.5x LabGenomics Co., Ltd. ( KOSDAQ:084650 ) is definitely...
New Risk • Dec 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩141.1b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 57% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩141.1b market cap, or US$96.4m).
분석 기사 • Oct 28LabGenomics Co., Ltd.'s (KOSDAQ:084650) Price Is Right But Growth Is LackingWith a price-to-sales (or "P/S") ratio of 2.1x LabGenomics Co., Ltd. ( KOSDAQ:084650 ) may be sending very bullish...
New Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 30% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
분석 기사 • May 19Insufficient Growth At LabGenomics Co., Ltd. (KOSDAQ:084650) Hampers Share PriceLabGenomics Co., Ltd.'s ( KOSDAQ:084650 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a strong buy...
분석 기사 • Apr 08Is LabGenomics (KOSDAQ:084650) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
공시 • Feb 21LabGenomics Co., Ltd., Annual General Meeting, Mar 26, 2025LabGenomics Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
New Risk • Jan 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 25% per year over the past 5 years.
분석 기사 • Jan 06There's No Escaping LabGenomics Co., Ltd.'s (KOSDAQ:084650) Muted Revenues Despite A 46% Share Price RiseLabGenomics Co., Ltd. ( KOSDAQ:084650 ) shareholders would be excited to see that the share price has had a great...
분석 기사 • Nov 17Not Many Are Piling Into LabGenomics Co., Ltd. (KOSDAQ:084650) Stock Yet As It Plummets 26%Unfortunately for some shareholders, the LabGenomics Co., Ltd. ( KOSDAQ:084650 ) share price has dived 26% in the last...
분석 기사 • Nov 08Is LabGenomics (KOSDAQ:084650) Weighed On By Its Debt Load?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Sep 21Slammed 29% LabGenomics Co., Ltd. (KOSDAQ:084650) Screens Well Here But There Might Be A CatchLabGenomics Co., Ltd. ( KOSDAQ:084650 ) shares have retraced a considerable 29% in the last month, reversing a fair...
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change).
분석 기사 • Aug 06Market Might Still Lack Some Conviction On LabGenomics Co., Ltd. (KOSDAQ:084650) Even After 35% Share Price BoostLabGenomics Co., Ltd. ( KOSDAQ:084650 ) shares have had a really impressive month, gaining 35% after a shaky period...
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
분석 기사 • Jul 27Is LabGenomics (KOSDAQ:084650) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
분석 기사 • Apr 09Market Still Lacking Some Conviction On LabGenomics Co., Ltd. (KOSDAQ:084650)LabGenomics Co., Ltd.'s ( KOSDAQ:084650 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...
New Risk • Mar 28New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Nov 21Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩4,050, the stock trades at a trailing P/E ratio of 72.7x. Average forward P/E is 40x in the Biotechs industry in South Korea. Total returns to shareholders of 9.9% over the past three years.
Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩21.00 loss per share (vs ₩232 profit in 3Q 2022)Third quarter 2023 results: ₩21.00 loss per share (down from ₩232 profit in 3Q 2022). Revenue: ₩21.2b (down 14% from 3Q 2022). Net loss: ₩1.55b (down 120% from profit in 3Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩3,670, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 28% over the past three years.
Buying Opportunity • Sep 25Now 23% undervaluedOver the last 90 days, the stock is up 35%. The fair value is estimated to be ₩6,026, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last 3 years. Earnings per share has grown by 4.3%.
Valuation Update With 7 Day Price Move • Aug 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩5,420, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 9.3% over the past three years.
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Share price has been volatile over the past 3 months (8.5% average weekly change). Profit margins are more than 30% lower than last year (18% net profit margin). Shareholders have been diluted in the past year (9.2% increase in shares outstanding).
Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩9,830, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 26% over the past three years.
Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩8,200, the stock trades at a trailing P/E ratio of 21x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total loss to shareholders of 9.6% over the past three years.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩6,470, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 5.5% over the past three years.
Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩1,429 (vs ₩2,481 in FY 2021)Full year 2022 results: EPS: ₩1,429 (down from ₩2,481 in FY 2021). Revenue: ₩144.8b (down 28% from FY 2021). Net income: ₩48.4b (down 42% from FY 2021). Profit margin: 33% (down from 41% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Mar 16Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩5,480, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 3.3% over the past three years.
공시 • Jan 19LabGenomics Co., Ltd. announced that it has received KRW 22.71198072 billion in fundingOn January 18, 2023, LabGenomics Co., Ltd. closed the transaction. The company amended the terms of the transaction. The company issued 3,128,372 shares at an issue price of KRW 7,260 per share for gross proceeds of KRW 22,711,980,720. The transaction included participation from Ruha Galacticos Co., Ltd., for 3,128,372 shares.
Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 21 April 2023. Payout ratio is a comfortable 4.5% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Oct 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩6,400, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 319% over the past three years.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩6,910, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 343% over the past three years.
Valuation Update With 7 Day Price Move • Aug 25Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to ₩6,780, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 369% over the past three years.
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩6,980, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 268% over the past three years.
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to ₩7,090, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 177% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Mar 16Investor sentiment improved over the past weekAfter last week's 41% share price gain to ₩31,700, the stock trades at a trailing P/E ratio of 5.5x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 334% over the past three years.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₩29,400, the stock trades at a trailing P/E ratio of 5.1x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total returns to shareholders of 329% over the past three years.
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩25,900, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 39x in the Biotechs industry in South Korea. Total returns to shareholders of 332% over the past three years.
Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improved over the past weekAfter last week's 33% share price gain to ₩31,400, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 394% over the past three years.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩24,750, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 38x in the Biotechs industry in South Korea. Total returns to shareholders of 205% over the past three years.
Valuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩29,250, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 221% over the past three years.
Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩34,300, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 43x in the Biotechs industry in South Korea. Total returns to shareholders of 321% over the past three years.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩32,550, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 48x in the Biotechs industry in South Korea. Total returns to shareholders of 272% over the past three years.
Valuation Update With 7 Day Price Move • May 28Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩23,350, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 116% over the past three years.
Valuation Update With 7 Day Price Move • Apr 26Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₩27,600, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 54x in the Biotechs industry in South Korea. Total returns to shareholders of 150% over the past three years.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩22,350, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 50x in the Biotechs industry in South Korea. Total returns to shareholders of 55% over the past three years.
분석 기사 • Mar 31If You Like EPS Growth Then Check Out LabGenomics (KOSDAQ:084650) Before It's Too LateIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Is New 90 Day High Low • Feb 22New 90-day low: ₩15,300The company is down 33% from its price of ₩22,750 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Jan 15New 90-day low: ₩15,850The company is down 54% from its price of ₩34,550 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 22% over the same period.
Is New 90 Day High Low • Dec 28New 90-day low: ₩17,500The company is down 51% from its price of ₩35,500 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period.
Is New 90 Day High Low • Dec 08New 90-day low: ₩20,600The company is down 48% from its price of ₩39,850 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Nov 10New 90-day low: ₩27,300The company is down 33% from its price of ₩40,800 on 12 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 22New 90-day low: ₩31,650The company is down 22% from its price of ₩40,450 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period.